BRAIN Biotech AG
XETRA:BNN

Watchlist Manager
BRAIN Biotech AG Logo
BRAIN Biotech AG
XETRA:BNN
Watchlist
Price: 3.44 EUR -0.86% Market Closed
Market Cap: 75.2m EUR
Have any thoughts about
BRAIN Biotech AG?
Write Note

BRAIN Biotech AG
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

BRAIN Biotech AG
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
BRAIN Biotech AG
XETRA:BNN
Income from Continuing Operations
-€8.8m
CAGR 3-Years
-15%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Wacker Chemie AG
XETRA:WCH
Income from Continuing Operations
€192.8m
CAGR 3-Years
-23%
CAGR 5-Years
8%
CAGR 10-Years
9%
Evonik Industries AG
XETRA:EVK
Income from Continuing Operations
€244m
CAGR 3-Years
-31%
CAGR 5-Years
-25%
CAGR 10-Years
-8%
Covestro AG
XETRA:1COV
Income from Continuing Operations
-€269m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
AlzChem Group AG
XETRA:ACT
Income from Continuing Operations
€34.8m
CAGR 3-Years
20%
CAGR 5-Years
39%
CAGR 10-Years
N/A
Symrise AG
XETRA:SY1
Income from Continuing Operations
€396.2m
CAGR 3-Years
5%
CAGR 5-Years
7%
CAGR 10-Years
N/A
No Stocks Found

BRAIN Biotech AG
Glance View

Market Cap
75.2m EUR
Industry
Chemicals

BRAIN Biotech AG is a technology company, which engages in the development and commercialization of bioactives, natural compounds, and proprietary enzymes. The company is headquartered in Zwingenberg, Hessen and currently employs 293 full-time employees. The company went IPO on 2016-02-09. Research & Development activities focus on bioactive natural compounds, tailored enzymes and high-performance microorganisms.

BNN Intrinsic Value
5.17 EUR
Undervaluation 33%
Intrinsic Value
Price

See Also

What is BRAIN Biotech AG's Income from Continuing Operations?
Income from Continuing Operations
-8.8m EUR

Based on the financial report for Jun 30, 2024, BRAIN Biotech AG's Income from Continuing Operations amounts to -8.8m EUR.

What is BRAIN Biotech AG's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
7%

Over the last year, the Income from Continuing Operations growth was -34%. The average annual Income from Continuing Operations growth rates for BRAIN Biotech AG have been -15% over the past three years , 7% over the past five years .

Back to Top